

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/781,262		02/18/2004	Geoffrey Smith	BWT-PT001.2	3996
3624	7590	09/26/2006		EXAMINER	
		ENIG, P.C.	BOESEN, AGNIESZKA		
UNITED PLAZA, SUITE 1600 30 SOUTH 17TH STREET			ART UNIT	PAPER NUMBER	
PHILADEI	LPHIA, P.	A 19103	1648		
				DATE MAILED: 09/26/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

X
N

	Application No.	Applicant(s)				
	10/781,262	SMITH ET AL.				
Office Action Summary	Examiner	Art Unit				
	Agnieszka Boesen	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period was preply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timused the second will expire SIX (6) MONTHS from a cause the application to become ABANDONE!	J.  lely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status	,					
1) Responsive to communication(s) filed on <u>18 Fe</u> 2a) This action is <b>FINAL</b> . 2b) ☐ This						
,						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims	,					
<ul> <li>4) ☐ Claim(s) 1-6 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdraw</li> <li>5) ☐ Claim(s) is/are allowed.</li> <li>6) ☐ Claim(s) is/are rejected.</li> <li>7) ☐ Claim(s) is/are objected to.</li> <li>8) ☐ Claim(s) 1-6 are subject to restriction and/or el</li> </ul>	·					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the I drawing(s) be held in abeyance. See tion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority document</li> <li>2. Certified copies of the priority document</li> <li>3. Copies of the certified copies of the priority application from the International Bureau</li> <li>* See the attached detailed Office action for a list</li> </ul>	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)  1) \( \sum \) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of References Cited (PTO-932)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate				

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, drawn to a medicament, comprising a recombinant poxvirus.

Group II, claim(s) 2-6, drawn to a detection method of an interaction of the chemokine-binding molecule with chemokine in the sample.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under unity of invention practice as it applies to cases filed under 35 U.S.C. 371, unity of invention between different categories of inventions will only be found to exist if specific combinations of inventions are present. Those combinations include:

- A) A product and a special process of manufacture of said product.
- B) A product and a process of use of said product.
- C) A product, a special process of manufacture of said product, and a process of use of said product.
- D) A process and an apparatus specially designed to carry out said process.
- E) A product, a special process of manufacture of said product, and an apparatus specially designed to carry out said process.

Application/Control Number: 10/781,262

Art Unit: 1648

The special technical feature of Group I is the recombinant poxvirus expressing a native A41L protein.

The special technical feature of Group II is detecting the interaction of the A41L protein with a chemokine, therefore this group does not comprise the recombinant poxvirus expressing a native A41L protein required for Group I.

Accordingly, Groups I and II are not so linked as to form a single general inventive concept and the claims lack unity of invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Page 4

Application/Control Number: 10/781,262

Art Unit: 1648

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Agnieszka Boesen whose telephone number is 571-272-8035. The examiner can normally be reached on M – F (9:00AM - 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 571-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Agnieszka Boesen

Stacy B. Chen 9/22/06 STACY B. CHEN PRIMARY EXAMINER